Detalhe da pesquisa
1.
Development and evaluation of a rapid one-step high sensitivity real-time quantitative PCR system for minor BCR-ABL (e1a2) test in Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).
Jpn J Clin Oncol
; 54(2): 153-159, 2024 Feb 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37986553
2.
Silent NK/T cell reactions to dasatinib during sustained deep molecular response before cessation are associated with longer treatment-free remission.
Cancer Sci
; 111(8): 2923-2934, 2020 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-32614159
3.
Risk Factors for Acute Kidney Injury and Chronic Kidney Disease following Allogeneic Hematopoietic Stem Cell Transplantation for Hematopoietic Malignancies.
Acta Haematol
; 143(5): 452-464, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-31822013
4.
[SLAM family proteins as therapeutic targets in multiple myeloma].
Rinsho Ketsueki
; 61(7): 818-826, 2020.
Artigo
em Japonês
| MEDLINE | ID: mdl-32759570
5.
Feasibility of the imatinib stop study in the Japanese clinical setting: delightedly overcome CML expert stop TKI trial (DOMEST Trial).
Int J Clin Oncol
; 24(4): 445-453, 2019 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-30421023
6.
Usefulness of BCOR gene mutation as a prognostic factor in acute myeloid leukemia with intermediate cytogenetic prognosis.
Genes Chromosomes Cancer
; 57(8): 401-408, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29663558
7.
[Amebic liver abscesses developing during R-CHOP chemotherapy in a patient with mantle cell lymphoma].
Rinsho Ketsueki
; 60(8): 929-931, 2019.
Artigo
em Japonês
| MEDLINE | ID: mdl-31484892
8.
Dasatinib cessation after deep molecular response exceeding 2 years and natural killer cell transition during dasatinib consolidation.
Cancer Sci
; 109(1): 182-192, 2018 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-29058817
9.
Full-length mutation search of the TP53 gene in acute myeloid leukemia has increased significance as a prognostic factor.
Ann Hematol
; 97(1): 51-61, 2018 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-28980058
10.
Clinical features and prognostic impact of PRDM16 expression in adult acute myeloid leukemia.
Genes Chromosomes Cancer
; 56(11): 800-809, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28710806
11.
Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse.
Blood
; 126(22): 2491-501, 2015 Nov 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-26438511
12.
D816 mutation of the KIT gene in core binding factor acute myeloid leukemia is associated with poorer prognosis than other KIT gene mutations.
Ann Hematol
; 96(10): 1641-1652, 2017 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-28762080
13.
Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.
Int J Clin Oncol
; 22(5): 972-979, 2017 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-28550414
14.
Adult T-cell leukemia-lymphoma complicated by Takotsubo cardiomyopathy and HTLV-1-associated myelopathy after treatment with the anti-CCR4 antibody mogamulizumab.
Rinsho Ketsueki
; 58(4): 309-314, 2017.
Artigo
em Japonês
| MEDLINE | ID: mdl-28484158
15.
Decision Analysis of Postremission Therapy in Cytogenetically Intermediate-Risk Acute Myeloid Leukemia: The Impact of FLT3 Internal Tandem Duplication, Nucleophosmin, and CCAAT/Enhancer Binding Protein Alpha.
Biol Blood Marrow Transplant
; 22(6): 1125-1132, 2016 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-27040395
16.
Clinical characteristics and prognosis of acute myeloid leukemia associated with DNA-methylation regulatory gene mutations.
Haematologica
; 101(9): 1074-81, 2016 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27247325
17.
JAK2 mutation and acute coronary syndrome complicated with stent thrombosis.
Heart Vessels
; 31(10): 1714-6, 2016 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26825737
18.
Mobile genetic element SCCmec-encoded psm-mec RNA suppresses translation of agrA and attenuates MRSA virulence.
PLoS Pathog
; 9(4): e1003269, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23592990
19.
Early cytotoxic lymphocyte expansion contributes to a deep molecular response to dasatinib in patients with newly diagnosed chronic myeloid leukemia in the chronic phase: results of the D-first study.
Am J Hematol
; 90(9): 819-24, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26103598
20.
Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: Results of the D-first study of Kanto CML study group.
Am J Hematol
; 90(4): 282-7, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25530131